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A B S T R A C T
Background: There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and
prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus
cisplatin/gemcitabine as ﬁrst-line treatment for advanced sqNSCLC patients, were evaluated.
Materials and methods: A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75mg/
m2, Day 1), gemcitabine (1250mg/m2, Days 1 and 8) and nintedanib (Days 2–7, 9–21) were given for 4–6 cycles,
followed by monotherapy until disease progression or adverse events (AEs). Two nintedanib doses were tested,
150mg twice daily (bid) and 200mg bid, to determine maximum tolerated dose (MTD) based on occurrence of
dose-limiting toxicities (DLTs) during Cycle 1. DLTs were primarily deﬁned as drug-related non-hematologic
(Grade ≥3) or hematologic (Grade 4) AEs.
Results: Sixteen patients were treated with nintedanib; n=4 for 150mg bid, n= 12 for 200mg bid. No DLTs
were observed in Cycle 1; therefore, the MTD was 200mg bid. In subsequent cycles, two patients had DLTs: renal
failure and reduced blood magnesium levels. The most common AEs were gastrointestinal. Three patients dis-
continued last study medication due to AEs and one had a nintedanib dose reduction. No relevant PK interactions
were observed. Five patients had partial responses (31.3%) and eight had stable disease (50.0%); disease control
rate was 81.3%. There were three long-term survivors (17–35 months).
Conclusions: The safety proﬁle of nintedanib 200mg bid plus cisplatin/gemcitabine was manageable, with AEs
consistent with previous observations. PK data demonstrated no interaction, and preliminary antitumor activity
was observed.
1. Introduction
Lung cancer is the most common cause of cancer mortality world-
wide, with an estimated 1.6 million deaths annually [1]. Non-small cell
lung cancer (NSCLC) accounts for 85% of all newly diagnosed cases,
with 30% of cases having squamous cell histology with 5-year survival
rates below 5% [2,3]. Platinum-based chemotherapy in combination
with paclitaxel, docetaxel, gemcitabine, or vinorelbine is recommended
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as the ﬁrst-line treatment for patients with advanced or metastatic
squamous NSCLC (sqNSCLC) [4,5], with necitumumab and pem-
brolizumab being recent addition to these options. Progress in the
treatment of sqNSCLC has been slow, and this study was designed to
assess the role of antiangiogenic therapy alongside standard therapy at
a time when few therapeutic options existed.
Proangiogenic pathways are an essential feature of NSCLC and re-
present important therapeutic targets [6]. Bevacizumab, a monoclonal
antibody targeting vascular endothelial growth factor (VEGF), im-
proved median overall survival (OS) and progression-free survival (PFS)
when used as ﬁrst-line combination therapy with platinum-based che-
motherapy [7]. Bevacizumab is not recommended for the treatment of
sqNSCLC as pulmonary hemorrhage in patients with squamous cell
histology receiving bevacizumab (phase II study) and bleeding (Grade
≥3) rates of ∼4% (phase III study) prompted the exclusion of this
histological type from most NSCLC studies with bevacizumab [7,8].
In contrast, continued combination therapy with thalidomide and
carboplatin/gemcitabine in selected patients with sqNSCLC (no pro-
gression after 2 cycles of treatment) showed PFS beneﬁt [9]. This
ﬁnding supported the current investigation of nintedanib in the treat-
ment of sqNSCLC. Nintedanib is an oral, angiokinase inhibitor, tar-
geting receptors in three proangiogenic pathways − VEGF receptors
(VEGFRs), platelet-derived growth factor receptors α/β and ﬁbroblast
growth factor receptors (FGFRs) [10]. FGFRs could be relevant ther-
apeutic targets as ampliﬁed FGFR1 occurs in ∼20% of patients with
sqNSCLC and may correlate with poor outcomes [3].
Nintedanib has a manageable safety proﬁle in combination with
docetaxel, pemetrexed and paclitaxel/carboplatin; [11] the maximum
tolerated dose (MTD) with all combinations was deﬁned at 200mg
twice daily (bid). The LUME-Lung 1 study evaluated nintedanib in
combination with docetaxel after ﬁrst-line treatment in patients with
advanced NSCLC. Nintedanib/docetaxel signiﬁcantly improved in-
dependently assessed PFS compared with placebo/docetaxel in the
overall study population, and provided signiﬁcant, clinically mean-
ingful improvement in OS in patients with adenocarcinoma, in parti-
cular in patients with aggressive tumors [12]. Combination therapy was
well tolerated, with a low frequency of fatal bleeding events (< 1.5%)
[13]. Nintedanib in combination with docetaxel is approved in several
countries, including the EU, for the treatment of locally advanced,
metastatic or locally recurrent NSCLC of adenocarcinoma tumor his-
tology after ﬁrst-line chemotherapy [14]. The objective of this phase I
study was to evaluate the safety, tolerability and pharmacokinetics (PK)
of nintedanib in combination with cisplatin/gemcitabine as ﬁrst-line
treatment of patients with advanced sqNSCLC.
2. Materials and methods
2.1. Study design
This open-label, dose-escalation study evaluated drug-related dose-
limiting toxicities (DLTs) and the safety and tolerability of nintedanib
used in combination with cisplatin/gemcitabine in patients with Stage
IIIB/IV sqNSCLC. The trial adhered to the principles of the Declaration
of Helsinki; multicenter ethics approval was obtained and all patients
provided written informed consent. This multicenter study was ori-
ginally planned as a two-part, Phase I/II study in patients with
sqNSCLC; however, the Phase II, double-blind, randomized, placebo-
controlled portion of the study was not performed.
2.2. Patients and treatment
Eligible patients (inclusion/exclusion criteria listed in
Supplementary table S1) received doses of 150mg or 200mg bid oral
nintedanib, with intravenous cisplatin (75mg/m2 on Day 1 of each 21-
day cycle) and gemcitabine (1250mg/m2 on Days 1 and 8 of each 21-
day cycle), plus standard premedication for chemotherapy on Days 1
and 8. Nintedanib was administered from Day 2 of each cycle, with no
intake on the days of chemotherapy (Days 1 and 8). The starting dose of
nintedanib was 150mg bid and, if no patients experienced a DLT during
the ﬁrst 21-day treatment cycle, the nintedanib dose was increased to
200mg bid for the next cohort. If one patient experienced a DLT, a
further three patients were to be recruited, increasing the cohort to six
patients; if no further patient experienced a DLT at 150mg bid, a fur-
ther three patients were treated at 200mg bid. If two or more of six
patients treated at this dose level experienced a DLT, three additional
patients were recruited to the lower-dose cohort. The MTD was deﬁned
as the dose of nintedanib added to cisplatin/gemcitabine at which no
more than one out of six patients experienced a DLT during Cycle 1.
Patients could receive 4–6 cycles of nintedanib in combination with
cisplatin/gemcitabine, after which daily doses of nintedanib mono-
therapy were given until disease progression or the occurrence of an
adverse event (AE) that contraindicated further treatment.
2.3. Assessments
2.3.1. Safety and tolerability
The primary endpoint was determination of the MTD based on the
occurrence of DLTs during Cycle 1; the MTD was deﬁned as the dose of
nintedanib added to cisplatin/gemcitabine at which no more than one
out of six patients experienced a drug-related DLT (or one dose tier
below the dose at which two or more out of six patients experienced a
drug-related DLT) during the ﬁrst 21-day treatment cycle. The fol-
lowing drug-related AEs were classiﬁed as DLTs at any time, according
to the Common Terminology Criteria for Adverse Events version 3.0:
Grade ≥3 non-hematologic AEs, excluding transient electrolyte ab-
normality, hyperuricemia and isolated elevation of gamma-glutamyl-
transferase; gastrointestinal toxicity (e.g. nausea, vomiting, diarrhea,
abdominal pain) or hypertension of Grade ≥3 despite optimal sup-
portive care/intervention; Grade ≥3 alanine aminotransferase and/or
aspartate aminotransferase elevation; and Grade 4 hematologic AEs,
including neutropenia that was uncomplicated (not associated with
fever ≥38.5 °C) for> 7 days (except for Cycle 1 where this deﬁnition
did not apply), febrile neutropenia associated with fever≥38.5 °C, and
platelet decrease to Grade 4, or to Grade 3 associated with bleeding or
requiring transfusions. Patient visits were scheduled for Days 1, 2, 8
(± 2 days), and 15 (± 2 days) during Cycles 1 and 2, Days 1
(± 2 days) and 8 (± 2 days) for Cycle 3 and in subsequent treatment
cycles. Any DLTs experienced after the start of the second treatment
period were considered separately from those in Cycle 1. All patients
who received at least one dose of any study medication were included
in the safety analysis. All AEs were recorded and safety was assessed
from the occurrence of AEs and changes in laboratory parameters.
Statistical methods were exploratory and descriptive. Analysis was
performed using SAS® version 9.2 (SAS Institute Inc., Cary, NC, US).
2.3.2. Eﬃcacy
Objective response/best overall response and PFS were determined
by investigator assessment (see Supplementary table S2).
2.3.3. PK
Blood samples for PK analyses were taken during Cycles 1 and 2 on
Days 1 and 2 for cisplatin/gemcitabine, and on Day 2 only for eva-
luation of nintedanib and its major metabolites. Cisplatin/gemcitabine
sampling was undertaken at 59 (immediately before the end of cisplatin
infusion), 120, 240, and 360min after the start of cisplatin infusion,
and at 29 (immediately before the end of gemcitabine infusion), 50, and
90min after the start of gemcitabine infusion. Nintedanib and meta-
bolite sampling was undertaken prior to nintedanib administration and
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1, 2, 4, 6, and 8 h post-administration. Plasma concentrations of nin-
tedanib, its metabolites, and gemcitabine were analyzed using validated
assays. Plasma concentrations of total and free platinum were analyzed
by a validated mass spectrometry method. PK calculations were per-




Patients were recruited at six centers in the UK, Spain, The
Netherlands and Italy, from February 2012 to June 2014. Twenty-one
patients were enrolled, and 16 were subsequently treated (Fig. 1). Five
patients were enrolled but not treated; one patient died prior to treat-
ment initiation, one had an AE that prevented treatment, and three did
not fulﬁl all of the inclusion criteria. Four patients were treated in the
nintedanib 150mg bid dose cohort; one extra patient being included in
addition to the planned three patients because of an administrative
error. Twelve patients were treated in the 200mg bid dose cohort;
demographic and clinical characteristics are shown in Table 1.
3.2. Treatment and dosing, DLTs and MTD
The median duration of nintedanib intake was 206 (range, 48–804)
days in the 150mg bid dose cohort and 100 (range, 5–264) days in the
200mg bid dose cohort. Dose reduction was necessary in one patient in
the 150mg bid dose cohort (none in the 200mg bid cohort). No DLTs
were observed in Cycle 1 in either dose group; thus, the MTD was es-
tablished as nintedanib 200mg bid.
Three patients in the 150mg bid dose cohort had Grade 3 or 4
hematologic toxicity during Cycle 1, an expected AE from cisplatin/
gemcitabine treatment, and this was not classiﬁed as a DLT by the in-
vestigators. Cycle 1 toxicities resolved in all three patients following
dose delay or reduction of gemcitabine alone, or both gemcitabine and
cisplatin for Cycle 2; in subsequent cycles, one patient experienced
recurrence of Grade 4 thrombocytopenia on two occasions, and another
reported Grade 3 thrombocytopenia. No dose modiﬁcations were made
for nintedanib in this group during Cycle 1 and no patients experienced
a DLT after Cycle 1.
In the 200mg bid dose cohort, one patient had Grade 4 neutropenia
during Cycle 1; this event was not considered to be a DLT by the in-
vestigator. Of the 12 patients treated with 200mg bid, two experienced
DLTs after Cycle 1. One patient had renal failure (Grade 3) and was
withdrawn from the study on Day 31. Investigator assessment suggested
that renal failure was likely to be cisplatin-related, but a relationship to
nintedanib could not be eliminated. In the other patient, Grade 3
hypomagnesemia persisting for 25 days was observed, and was con-
sidered to be drug-related. No action was taken and the patient re-
covered.
3.3. Adverse events
All 16 patients experienced at least one treatment-related AE
(Table 2). Three patients, all in the 200mg bid dose cohort, dis-
continued last study medication after the ﬁrst treatment cycle. The
reasons for discontinuation were dyspnea and dysphagia (considered
unrelated to the study treatment), and renal failure (discussed above).
Seven patients (43.8%) had serious AEs: two patients treated with
nintedanib 150mg bid, and ﬁve patients treated with nintedanib
200mg bid. Two serious AEs were fatal (both in the 200mg bid cohort),
with the causes of death being dyspnea and sudden death. Both were
considered to be related to underlying disease progression and not
Fig. 1. LUME-Lung 3 patient enrolment and study design ﬂow
diagram.
*According to the 3+3 study design, only three patients
should have been treated, but one additional patient was in-
cluded in the 150mg bid dose cohort because of an adminis-
trative error.
AE, adverse event; bid, twice daily; DLT, dose-limiting toxicity;
PD, progressive disease.
Table 1










Male 4 (100) 11 (91.7) 15 (93.8)
Female 0 1 (8.3) 1 (6.3)
Race, n (%)
White 4 (100) 12 (100) 16 (100)
Smoking history, n (%)
Ex-smoker 3 (75.0) 6 (50.0) 9 (56.3)
Current smoker 1 (25.0) 6 (50.0) 7 (43.8)
ECOG PS, n (%)
0 2 (50.0) 3 (25.0) 5 (31.3)
1 2 (50.0) 9 (75.0) 11 (68.8)
Age, years
Median (range) 61.0 (56–80) 65.0 (55–72) 64.5
(55–80)
Time from ﬁrst diagnosis, months
Median (range)a 0.99 (0.5–1.0) 0.89 (0.3–2.3) 0.92
(0.3–2.3)
Number of metastatic sites at screeningb
Median (range) 2.0 (1–3) 2.5 (1–4) 2.0 (1–4)
Patients with prior
chemotherapy, n (%)
0 1c (8.3) 1 (6.3)
bid, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance
status.
a Missing= 1.
b Documented by the investigator.
c One patient had received two courses of cisplatin as adjuvant che-
motherapy 5 years prior to entering this study, which was not a protocol vio-
lation.
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study treatment. Common individual any-grade AEs were nausea, vo-
miting, constipation, decreased appetite, and diarrhea. The majority of
hematologic AEs were reported during Cycle 1. A total of four patients
had AEs that led to a dose reduction of cisplatin, gemcitabine or both.
Only one patient had an AE that led to a dose reduction from nintedanib
150mg to 100mg.
As expected with cisplatin/gemcitabine treatment, the most
common changes in laboratory parameters were the reduction in
Table 2





All grades Grade ≥3 All grades Grade ≥3
Patients with any AE, n (%) 4 (100) 4 (100) 12 (100) 12 (100)
Patients with any drug-related AE; all courses, n (%) 4 (100) 4 (100) 12 (100) 11 (91.7)
Patients with DLT in Cycle 1, n (%) 0 0 0 0
Patients with any drug-related AE; Cycle 1, n (%) 4 (100) 3 (75.0) 10 (83.3) 5 (41.7)
Patients with any AE; Cycle 1, n (%) 4 (100) 3 (75.0) 10 (83.3) 5 (41.7)
Any AEs by worst CTCAE grade during Cycle 1 occurring at Grade ≥3
Thrombocytopenia 3 (75.0) 3 (75.0) 2 (16.7) 0
Neutropenia 3 (75.0) 2 (50.0) 2 (16.7) 1 (8.3)
Decreased white blood cell count 0 0 2 (16.7) 1 (8.3)
Hypertension 0 0 2 (16.7) 1 (8.3)
Increased GGT 0 0 1 (8.3) 1 (8.3)
Decreased platelet count 0 0 1 (8.3) 1 (8.3)
Spontaneously reported AEs during on-treatment period, all coursesa
Nausea 4 (100) 0 9 (75.0) 0
Vomiting 2 (50.0) 0 8 (66.7) 0
Dyspepsia 2 (50.0) 0 0 0
Epistaxis 2 (50.0) 0 0 0
Diarrhea 4 (100) 1 (25.0) 5 (41.7) 0
Constipation 1 (25.0) 0 8 (66.7) 0
Decreased appetite 4 (100) 0 5 (41.7) 0
Dyspnea 3 (75.0) 0 5 (41.7) 2 (16.7)
Thrombocytopenia 3 (75.0) 3 (75.0) 4 (33.3) 0
Neutropenia 3 (75.0) 2 (50.0) 4 (33.3) 4 (33.3)
Asthenia 1 (25.0) 0 6 (50.0) 2 (16.7)
Cough 2 (50.0) 1 (25.0) 4 (33.3) 0
Weight decreased 2 (50.0) 0 4 (33.3) 0
Anemia 2 (50.0) 0 3 (25.0) 2 (16.7)
Rash 2 (50.0) 0 3 (25.0) 0
Alopecia 1 (25.0) 0 4 (33.3) 0
Insomnia 1 (25.0) 0 4 (33.3) 0
Hypertension 0 0 4 (33.3) 2 (16.7)
Arthralgia 1 (25.0) 0 2 (16.7) 1 (8.3)
Increased blood creatinine 0 0 3 (25.0) 1 (8.3)
Pruritis 2 (50.0) 0 1 (8.3) 0
Dizziness 2 (50.0) 0 1 (8.3) 0
Headache 2 (50.0) 0 1 (8.3) 0
Lower respiratory tract infection 2 (50.0) 1 (25.0) 1 (8.3) 0
Increased ALT 1 (25.0) 1 (25.0) 1 (8.3) 0
Decreased platelet count 0 0 2 (16.7) 1 (8.3)
Decreased white blood cell count 0 0 2 (16.7) 1 (8.3)
Hyponatremia 0 0 2 (16.7) 1 (8.3)
Increased blood uric acid 0 0 2 (16.7) 1 (8.3)
Increased GGT 0 0 2 (16.7) 1 (8.3)
Hypokalemia 0 0 1 (8.3) 1 (8.3)
Dysphagia 0 0 1 (8.3) 1 (8.3)
Fatigue 1 (25.0) 0 4 (33.3) 1 (8.3)
Pneumonia aspiration 0 0 1 (8.3) 1 (8.3)
Pneumonia 0 0 2 (16.7) 2 (16.7)
Hypomagnesemia 0 0 1 (8.3) 1 (8.3)
Renal failure 0 0 1 (8.3) 1 (8.3)
Lymphangiosis carcinomatosa 0 0 1 (8.3) 1 (8.3)
Sudden death 0 0 1 (8.3) 1 (8.3)
Worst CTCAE grade for AEs based on laboratory values during on treatment period
Hemoglobin 4 (100.0) 0 12 (100.0) 1 (8.3)
White blood cell count 4 (100.0) 1 (25.0) 10 (83.3) 4 (33.3)
Platelets 4 (100.0) 3 (75.0) 11 (91.7) 2 (16.7)
Neutrophils 4 (100.0) 3 (75.0) 11 (91.7) 4 (33.3)
Percentages are calculated based on the total number of patients in each cohort. An individual patient could contribute to several items.
Elevations in hepatic enzymes were analyzed in more detail because of the known safety proﬁle of nintedanib. One patient in the nintedanib 150mg bid group had
maximum ALT and AST values 3 x ULN and another patient in this group had ALT 5 x ULN. Three patients (75.0%) in the nintedanib 150mg bid group and two
patients (16.7%) in the 200mg bid group had alkaline phosphatase levels> 1.5 x ULN. However, no patients had indications of drug-induced liver injury.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; bid, twice daily; CTCAE, Common Terminology Criteria for Adverse Events; DLT,
dose-limiting toxicity; GGT, gamma-glutamyltransferase; ULN, upper limit of normal.
a AEs shown are those that occurred in>25% of patients at any grade in either treatment arm or in at least one patient in either treatment arm at Grade ≥3.
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platelets, hemoglobin, neutrophils and white blood cells (Table 2).
3.4. PK
Plasma concentrations of nintedanib peaked between 2 and 6 h after
drug intake in most patients (Table 3). Nintedanib exposure was gen-
erally higher on Day 2 of Cycle 2 compared with the exposure observed
after the ﬁrst dose administration on Day 2 of Cycle 1, due to accu-
mulation after repeated dosing (factor of approximately 2). These were
not representative of steady-state values because the nintedanib dose on
Day 1/Cycle 2 was omitted (steady state is reached after 1 week of
continuous bid dosing). The variability of the PK parameters area under
the curve (AUC) and maximum plasma concentration (Cmax) was very
high, with the coeﬃcient of variation for geometric coeﬃcient of var-
iation values being in the range of 72.4–193% (Table 3). No terminal
half-life (t1/2) or related PK parameters were calculated for nintedanib
due to the limited sampling duration (up to 8 h after drug administra-
tion). There were no substantive changes in key PK parameters of
gemcitabine or cisplatin (AUC, t1/2, Cmax) in the presence of nintedanib
(see Supplementary Fig. S1 and S2 and Table S3).
3.5. Eﬃcacy
All patients were evaluated for response to treatment, ﬁve patients
had a partial response (PR) and eight patients had stable disease (SD),
giving an overall response rate of 31.3% (5/16) and a disease control
rate of 81.3% (13/16) (Supplementary table S4). Median OS was 6.7
months (95% conﬁdence interval [CI]: 4.4–not estimable; eight deaths).
The 6-month OS rate was 69% (95% CI: 46–92). Median PFS was 4.2
months (95% CI: 2.6–6.0; 14 events) and the 6-month PFS rate was 25%
(95% CI: 4–46%). There were three long-term survivors with survival
(and best overall response) of 17 months (SD), 19 months (PR) and 35
months (SD), respectively, and a corresponding PFS of 6.0, 8.4 and 35.0
months; all responses were unconﬁrmed. One patient in the 150mg bid
cohort remains on treatment (57 months, as of November 2016).
4. Discussion
In patients with advanced sqNSCLC, nintedanib 200mg bid com-
bined with cisplatin/gemcitabine at standard doses has a tolerable
safety proﬁle with no DLTs observed in Cycle 1. A dose of nintedanib
200mg bid is consistent with that used in other cancer studies [15–17].
Common AEs included hematologic and gastrointestinal toxicities.
The hematologic AEs reported here are those commonly observed with
cisplatin/gemcitabine, and the addition of nintedanib did not increase
the toxicity rate [18]. The mild-to-moderate gastrointestinal AEs
reported (including diarrhea) are similar to those seen with nintedanib
monotherapy or in combination with chemotherapy [12,19]. Im-
portantly, no unexpected AEs were reported and those commonly as-
sociated with other antiangiogenic agents, such as thromboembolic
events, gastrointestinal perforation, and proteinuria, were not ob-
served; [20] hypertension was reported in four patients, at Grade≥3 in
two patients. Importantly, there were no Grade ≥3 bleeding AEs in
either dose group. These AEs were generally expected and manageable,
and consistent with previous Phase I trials [21,22].
Nintedanib absorption after oral administration was rapid in com-
bination with cisplatin/gemcitabine with comparable values to those
previously reported with monotherapy [23]. The similarity of the PK
data suggests that cisplatin/gemcitabine has no clinically relevant ef-
fect on the PK characteristics of nintedanib, whereas continuous
treatment with nintedanib did not alter the PK parameters of cisplatin/
gemcitabine. Total platinum exposure was slightly higher following
repeated nintedanib dosing, possibly due to the long half-life and ac-
cumulation, but not due to any PK interaction [24,25]. Nintedanib and
its metabolites do not interfere with cytochrome P450 (CYP450) en-
zymes, and drug–drug interactions due to CYP450 involvement are
considered to be unlikely. This is an advantage because other agents
used in combination with cisplatin/gemcitabine have the potential to
be CYP450 substrates and/or inhibitors. Co-administration of ninte-
danib with cisplatin/gemcitabine is, therefore, a viable combination for
future trials.
Initially, it was suspected that the strategy of combining anti-
angiogenic agents with chemotherapy would only beneﬁt patients with
non-squamous NSCLC, as patients with sqNSCLC faced increased
bleeding risks. This study, combining a VEGFR inhibitor with cisplatin/
gemcitabine for sqNSCLC, showed no serious bleeding events and
contrasts with results for other small-molecule VEGFR inhibitors
[26,27]. Although the number of patients treated in our study is small,
the observed response rate seen with nintedanib and cisplatin/gemci-
tabine with three long-term survivors suggests promising clinical ac-
tivity. Additionally, size is another limitation of the current study and,
since the design of the LUME-Lung 3 study, the sqNSCLC treatment
landscape has changed dramatically [4]. Necitumumab, in combination
with cisplatin/gemcitabine, is recommended in European guidelines for
the ﬁrst-line treatment of epidermal growth factor receptor (EGFR)-
expressing metastatic sqNSCLC [5]. More signiﬁcantly, treatment of
sqNSCLC can be addressed using therapies targeting programmed cell
death-1 or programmed cell death-ligand 1 (PD-L1) [28–34]. Although
not an optimal biomarker, measurement of PD-L1 expression is now
recommended before ﬁrst-line treatment in patients with metastatic
NSCLC, including sqNSCLC [4]. In this respect, pembrolizumab, as
monotherapy, is approved for the ﬁrst-line treatment of metastatic
Table 3
PK parameters for the nintedanib 200mg bid (MTD) dose group by treatment cycle.
Cycle 1 Cycle 2
Nintedanib BIBF 1202 BIBF 1202 glucoronide Nintedanib BIBF 1202 BIBF 1202 glucoronide
AUC0-12 (ng h/mL)
gMean 167 248 – 228 253 2370
gCV (%) 73.0 183 – 105 118 72.4
Cmax (ng/mL)
gMean 23.6 24.1 15.2 34.4 34.3 177
gCV (%) 93.9 193 137 123 143 113
tmax (h)a
Median 6.0 6.0 8.0 4.0 4.0 6.0
Range (%) (1.0–8.0) (2.0–8.0) (6.0–8.0) (2.0–6.0) (4.0–8.00) (0.0–8.0)
Note that extrapolation using λz was used to calculate AUC0–12; nintedanib plasma was only sampled up to 8 h after drug intake, thus the corresponding plasma
concentration–time proﬁle does not cover the whole dosing interval of 12 h. Data shows parent compound and metabolites (BIBF 1202 and BIBF 1202 glucoronide).
AUC, area under the curve; Cmax, maximum plasma concentration; gCV, geometric coeﬃcient of variation; gMean, geometric mean; MTD, maximum tolerated dose;
PK, pharmacokinetics; tmax, time to maximum plasma concentration.
a Median and range.
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NSCLC in adults whose tumors express PD-L1 with a ≥50% tumor
proportion score without EGFR or ALK tumor mutations [29,30].
Pembrolizumab has also been approved for the treatment of advanced
or metastatic NSCLC in adults whose tumors express PD-L1 with a≥1%
tumor proportion score and who have received at least one prior che-
motherapy regimen. The immunotherapy agents nivolumab and ate-
zolizumab are indicated for the treatment of locally advanced or me-
tastatic NSCLC for after platinum-based chemotherapy [28,31,33,35].
In combination with docetaxel, ramucirumab is also indicated for the
treatment of locally advanced or metastatic sqNSCLC after platinum-
based chemotherapy [31,33]. Given these developments, future clinical
investigation of combination treatment with antiangiogenic agents and
programmed death receptor-1 inhibitors may be warranted.
5. Conclusions
Continuous dosing of nintedanib 200mg bid when combined with
standard doses of cisplatin/gemcitabine shows a manageable safety
proﬁle in line with previous studies. PK data demonstrate no relevant
interaction, and the combination showed antitumor activity in patients
with sqNSCLC. These observations support further evaluation of this
combination in trials. In addition, successful identiﬁcation of predictive
biomarkers could enable enrichment of the patient population, and
increase the chance of ﬁnding a clinical beneﬁt.
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